文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

多西环素暴露后预防在男男性行为者中的皮肤不良反应:多中心真实世界研究

Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

本研究为多中心回顾性队列研究,纳入2023年10月至2025年2月期间启动多西环素暴露后预防(doxy-PEP)的671名男男性行为者(MSM),其中460名HIV感染者、211名暴露前预防使用者。9人(1.3%)出现皮肤反应,发生率1.0/100人年,以固定性药疹为主(8例),另1例光敏反应,均在暴露后24小时内出现,全部停药,症状1-3周内缓解。既往对任何药物有过敏反应者发生皮肤不良反应的风险更高(OR 6.99,95%CI 1.83-26.65)。

要点

  • doxy-PEP相关皮肤不良反应发生率低(1.3%),以固定性药疹为主,但均导致停药。
  • 既往任何药物过敏史者皮肤不良反应风险显著升高(OR 6.99)。
  • 启动doxy-PEP前应详细询问药物过敏史,用药期间监测皮肤反应。

核心结论

  • doxy-PEP相关皮肤不良反应通常较轻,但会导致停药,应重视用药前过敏史采集和用药中皮肤监测。

研究设计与样本

  • 多中心回顾性队列研究,纳入2023年10月至2025年2月启动doxy-PEP的671名MSM,其中460名HIV感染者、211名暴露前预防使用者。

主要发现

  • 9人(1.3%)出现皮肤反应,发生率为1.0/100人年。
  • 皮肤反应以固定性药疹为主(8例),另1例为光敏反应,通常在暴露后24小时内出现。
  • 所有9人均停用doxy-PEP,症状在1-3周内缓解。
  • 既往对任何药物有过敏反应者发生皮肤不良反应的风险更高(OR 6.99,95%CI 1.83-26.65)。
  • 所有出现皮肤不良反应者既往均曾治疗性使用多西环素,但仅3人报告过对多西环素过敏。

临床怎么用

  • 启动doxy-PEP前应详细询问药物过敏史,尤其关注既往任何药物过敏反应。
  • 用药期间应警惕固定性药疹和光敏反应,告知患者出现皮疹及时报告并停药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Doxycycline has demonstrated a favourable safety profile in clinical trials of post-exposure prophylaxis (doxy-PEP) for sexually transmitted infections; however, potential adverse effects may limit its feasibility. We aimed to investigate dermatological adverse effects of doxy-PEP in real-world settings. METHODS: This multicentre retrospective cohort study was conducted between October 2023 and February 2025, following the implementation of doxy-PEP among MSM. Individuals were encouraged to report adverse effects after initiating doxy-PEP. Data on medical history, previous therapeutic doxycycline exposure and history of allergic reactions were collected from electronic medical records. RESULTS: A total of 671 MSM were included, comprising 460 people with HIV and 211 on pre-exposure prophylaxis. Among them, nine individuals (1.3%) developed skin reactions, with an incidence rate of 1.0 per 100 person-years. Most were fixed drug eruptions (n = 8), with one case of photosensitivity. These reactions typically appeared within 24 h of exposure; and all nine individuals discontinued doxy-PEP, and symptoms resolved within 1-3 weeks. Individuals with a prior history of allergic reactions to any medication were at greater risk of experiencing adverse skin reactions (odds ratio, 6.99; 95% CI, 1.83-26.65). Notably, all individuals who experienced dermatological adverse events had previously used therapeutic doxycycline, though only three reported prior allergic reactions to it. CONCLUSIONS: Although dermatological adverse events associated with doxy-PEP were generally mild, they led to discontinuations. These findings underscore the importance of obtaining a thorough history of drug allergy before initiating doxy-PEP and highlight the need for vigilant monitoring of dermatological adverse events during its use.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Chen LY, Lin WT, Chen YT, et al. Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study. J Antimicrob Chemother. 2025. PMID: 41054936. doi:10.1093/jac/dkaf351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。